Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial
Attaya Suvannasankha(Indiana University Health), Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), Patrick J. Mueller(Bristol-Myers Squibb (Switzerland)), Margaret Hoyle(The Fertilizer Institute), Ashraf Badros(University of Maryland, Baltimore), Jonathan L. Kaufman(Emory University), Michel Pavic(University of Bologna), Parth Shah(Dartmouth–Hitchcock Medical Center), Hock Choong Lai(Cancer Council Queensland), Erik Vandendries(Pfizer (United States)), Muhammad Sheraz Raza(Dr. Everett Chalmers Regional Hospital), Jorge Acosta‐Reyes(Bristol-Myers Squibb (Switzerland))
Cited by 6
Related Papers
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
|The Journal of Immunology|2011|894